Read more

March 10, 2020
1 min read
Save

How will a wearable monitoring tool revolutionize mental health care? — top stories in psychiatry

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A new pilot program at Texas A&M aims to revolutionize how universities track the mental health of students, according to last week’s top story in psychiatry.

Another top story includes new study data that show widowhood may accelerate the clinical progression of Alzheimer’s disease.

Read these and more top stories in psychiatry below:

Q&A: How a wearable monitoring tool may revolutionize mental health care

With mental health issues becoming more prevalent on college campuses, researchers are working to help students more easily obtain mental health care by developing a wearable continuous monitoring tool. Read more.

Widowhood, Alzheimer's disease biomarker linked to cognitive decline among older adults

Widowhood may accelerate cognitive decline and Alzheimer’s disease clinical progression, according to a study published in JAMA Network Open. Read more.

 
With mental health issues becoming more prevalent on college campuses, researchers are working to help students more easily obtain mental health care by developing a wearable continuous monitoring tool.
Source: Adobe Stock

Suicide risk significantly elevated at night

Suicide risk is higher at night than any other time of day, according to a study published in the Journal of Clinical Psychiatry. Researchers found no significant variation in this risk by method, month or demographic characteristics. Read more.

Varenicline curbs alcohol craving but fails to improve drinking-related outcomes

Varenicline appeared to reduce alcohol craving among individuals with alcohol use disorders, but it did not improve drinking-related outcomes, according to results of a systematic review and meta-analysis published in Journal of Clinical Psychiatry. Read more.

Psychedelics appear promising for treating psychiatric disorders, but more research needed

The current body of research regarding psychedelics has produced insufficient evidence to recommend FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders, according to study findings published in American Journal of Psychiatry. However, researchers noted the need to further study the efficacy of psychedelics for treating psychiatric disorders. Read more.